Anzeige
Mehr »
Login
Freitag, 29.03.2024 Börsentäglich über 12.000 News von 687 internationalen Medien

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3ERKM | ISIN: CA88338H7040 | Ticker-Symbol: TQ80
Frankfurt
28.03.24
21:50 Uhr
1,400 Euro
+0,180
+14,75 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
THERATECHNOLOGIES INC Chart 1 Jahr
5-Tage-Chart
THERATECHNOLOGIES INC 5-Tage-Chart
RealtimeGeldBriefZeit
1,4301,63028.03.

Aktuelle News zur THERATECHNOLOGIES Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DoStocks in Play: Theratechnologies Inc.3
DoTheratechnologies to Present Preclinical Data at AACR on Multiple PDCs Showcasing Potential of SORT1+Technology Platform2
22.03.Theratechnologies Inc (2): Theratechnologies to cut preclinical cancer research1
22.03.Theratechnologies phases down preclinical oncology research1
22.03.Theratechnologies shifts focus, phases down preclinical research1
22.03.Theratechnologies Announces Update on its Preclinical Oncology Research Program60Company continues to shift to commercial focus as it seeks partners to advance R&D MONTREAL, March 22, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. ("Theratechnologies" or the "Company") (TSX:...
► Artikel lesen
22.03.Theratechnologies Inc (2): Theratechnologies appoints Zwick as director1
22.03.Theratechnologies Appoints Jordan Zwick to its Board of Directors1
21.03.Theratechnologies Inc. - 6-K, Report of foreign issuer1
21.03.Theratechnologies Inc (2): Theratechnologies increases dose level in phase 1 trial1
21.03.Theratechnologies Initiates Increased Dose Level in Phase 1 Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian Cancer54Medical Review Committee approved initiation of recruitment of next cohort of patients, in alignment with dose optimization protocol First patient out of six already enrolled and treated with initial...
► Artikel lesen
29.02.Alain Trudeau steps down from Theratechnologies board1
29.02.Theratechnologies Inc (2): Theratechnologies director Trudeau resigns1
29.02.Theratechnologies Announces the Resignation of One of Its Directors, Mr. Alain Trudeau1
27.02.Theratechnologies Inc. - 6-K, Report of foreign issuer1
27.02.Theratechnologies stock plunges after FDA denies review of Trogarzo sBLA1
27.02.Theratechnologies Receives Refusal to File Letter for Trogarzo Intramuscular Method of Administration sBLA from FDA148MONTREAL, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. ("Theratechnologies" or the "Company") (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization...
► Artikel lesen
23.02.Theratechnologies Inc reports results for the quarter ended in November - Earnings Summary 1
22.02.Earnings call: Theratechnologies reports record sales, optimistic outlook2
21.02.THTX stock keeps "Buy" rating at Research Capital2
Seite:  Weiter >>
101 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1